唑吡坦治疗音乐家肌张力障碍的疗效与安全性
Efficacy and Safety of Zolpidem for Musician's Dystonia.
作者信息
Horisawa Shiro, Kim Kilsoo, Murakami Masato, Nishitani Masahiko, Kawamata Takakazu, Taira Takaomi
机构信息
Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.
出版信息
J Mov Disord. 2024 Oct;17(4):425-429. doi: 10.14802/jmd.24121. Epub 2024 Jul 1.
OBJECTIVE
The efficacy and safety of zolpidem for treating musician's dystonia are not well understood. We aimed to retrospectively investigate the efficacy and safety of zolpidem for treating musician's dystonia.
METHODS
We retrospectively reviewed medical records between January 2021 and December 2023 to identify patients with musician's dystonia who had been prescribed zolpidem. Tubiana's Musician's Dystonia Rating Scale (range, 1-5; lower scores indicating greater severity) was used to evaluate musician's dystonia.
RESULTS
Fifteen patients were included in this study. The mean effective dose of zolpidem was 5.3 ± 2.0 mg. The mean effective duration of zolpidem was 4.3 ± 1.2 h. With zolpidem administration, Tubiana's musician's dystonia rating scale score significantly improved from 2.2 ± 1.0 to 4.3 ± 0.8 (48.9% improvement, p < 0.001). Two patients (13.3%) discontinued the drug owing to unsatisfactory results or sleepiness.
CONCLUSION
The results of this study suggest that zolpidem may be an alternative treatment option for musician's dystonia.
目的
唑吡坦治疗音乐家肌张力障碍的疗效和安全性尚不清楚。我们旨在回顾性研究唑吡坦治疗音乐家肌张力障碍的疗效和安全性。
方法
我们回顾性分析了2021年1月至2023年12月期间的病历，以确定接受唑吡坦治疗的音乐家肌张力障碍患者。使用图比亚纳音乐家肌张力障碍评定量表（范围为1-5；分数越低表明病情越严重）来评估音乐家肌张力障碍。
结果
本研究纳入了15名患者。唑吡坦的平均有效剂量为5.3±2.0毫克。唑吡坦的平均有效持续时间为4.3±1.2小时。使用唑吡坦后，图比亚纳音乐家肌张力障碍评定量表评分从2.2±1.0显著提高到4.3±0.8（提高了48.9%，p<0.001）。两名患者（13.3%）因效果不佳或嗜睡而停药。
结论
本研究结果表明，唑吡坦可能是治疗音乐家肌张力障碍的一种替代治疗选择。
Zotero 插件